BlossomHill is a clinical-stage biopharmaceutical company developing small molecule cancer therapies through rational, structure-based drug design. The company creates new chemical scaffolds to overcome structural vulnerabilities that allow cancer cells to develop resistance to existing treatments. Its lead asset, BH-30643, is an oral EGFR inhibitor for non-small cell lung cancer designed to target the C797S resistance mutation, a condition with no currently approved oral targeted therapy. BH-30643 is in a Phase 1/2 global trial, and the company plans to initiate a pivotal Phase 2 trial in Q1 2027 to seek accelerated FDA approval. BlossomHill is also developing BH-30236, a CLK inhibitor in Phase 1 trials for patients with acute myeloid leukemia and myelodysplastic syndromes who have failed standard venetoclax-based treatments. A third candidate, BH-501284, is a preclinical pan-KRAS inhibitor with an IND submission planned for Q1 2027. BlossomHill currently generates no revenue and funds its research and development through equity financing. The company's path to revenue depends on successfully advancing these candidates through clinical trials to regulatory approval and commercial drug sales. BlossomHill’s leadership includes the founders of Turning Point Therapeutics, who apply their expertise in macrocyclic design to target mutations that drive cancer resistance.